Literature DB >> 17984134

Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?

Stephan von Haehling, Mitja Lainscak, Stefan D Anker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17984134     DOI： 10.1093/eurheartj/ehm493

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  7 in total

1.  Drug treatment for obesity in the post-sibutramine era.

Authors:  Bernard M Y Cheung
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

Review 2.  Obesity in 2010: the future of obesity medicine: where do we go from here?

Authors:  Suzanne M Wright; Louis J Aronne
Journal:  Nat Rev Endocrinol       Date:  2011-02       Impact factor: 43.330

3.  Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study.

Authors:  Mira Harrison-Woolrych; Janelle Ashton; Peter Herbison
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

Review 4.  Sibutramine on cardiovascular outcome.

Authors:  André J Scheen
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

5.  Pharmacotherapies for obesity: past, current, and future therapies.

Authors:  Lisa L Ioannides-Demos; Loretta Piccenna; John J McNeil
Journal:  J Obes       Date:  2010-12-12

6.  No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight.

Authors:  D L Smith; H T Robertson; R A Desmond; T R Nagy; D B Allison
Journal:  Int J Obes (Lond)       Date:  2010-11-16       Impact factor: 5.095

7.  A case of dilated cardiomyopathy with massive left ventricular thrombus after use of a sibutramine-containing slimming product.

Authors:  Seung Hye Heo; Min-Ho Kang
Journal:  Korean Circ J       Date:  2013-09-30       Impact factor: 3.243
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.